1King JF, Grant A, Keirse MJ, et al. Beta-mimetics in preterm labour : an overview of the randomized controlled trials [J]. Br J Obstet Gynaecol, 1988, 95 ( 3 ) :211-222.
2The Worldwide Atosiban Versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus betaadrenergic agonists in the treatment of preterm labour[J]. Br J Obstet Gynaecol, 2001,108 : 133-142.
3The European Atosiban Study Group. The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor: a randomized, double-blind, controlled study [ J ]. Acta Obstet Gynecol Scand ,2001,80( 5 ) :413-422.
4Samol JM, Lambers DS. Magnesium sulfate tocolysis and pulmonary edema: the drug or the vehicle? [J]. Am J Obstet Gynecol,2005,192 ( 5 ) : 1430-1432.
5Olson DM, Ammann C. Role of the prostaglandins in labour and prostaglandin receptor inhibitors in the prevention of preterm labour[ J]. Front Biosci, 2007,12 : 1329-1343.
6Groom KM, Shennan AH. TOCOX-a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor ) for the prevention of preterm delivery in women at high risk[J]. BJOG,2005,112(6) :725-730.
7Di Renzo GC, Roura LC. The European Association of perinatal medicine-study group on preterm birth. Guidelines for the management of spontaneous preterm labor [J]. J Perinat Med, 2006, 34:359-363.
8Lees C, Campbell S. Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor [ J ]. Lancet, 1994,343 (8909) : 1325-1326.
9Joseph KS, Kramer MS, Marcoux S, Ohlsson A, Wen SW, Allen A, et al. Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992 through 1994[J]. N Engl J Med, 1998 , 339(20):1434-1439.
